YOLFTbeta
35

NH Special Purpose Acquisition 17 Co. Ltd.

359090 · KQ · Healthcare / Health Information Services

2,095.00KRW+141.00 (+7.22%)

Price History

Full chart

Market Stats

Previous Close1,954.00
Open1,950.00
Day Range1,950.00 – 2,140.00
52-Week Range1,667.00 – 5,824.92
Volume68.85K
Market Cap26.21B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield2.19%
Beta0.04
50-Day Avg2,036.86
200-Day Avg3,222.37

About

C&R Research Inc. engages in the of clinical development for pharmaceuticals and medical devices. The company's therapeutic area comprises oncology, cardiovascular, endocrinology, dermatology, central nervous system, ophthalmology, and rare disease.The company was founded in 1997 and is based in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryHealth Information Services
  • CEOMr. Moontae Yoon
  • Employees482
  • HeadquartersC&R Building, 412, Seoul, South Korea, Korea
  • Websitehttps://www.cnrres.com

Leadership

  • Mr. Moontae YoonCEO & Director · b. 1951
  • Jinhak KimPresident
  • Ms. Jo SukjeongGM of Technology & MD · b. 1971
  • Mr. Byungin YoonFuture Strategy Director & Director · b. 1980
  • Mr. Byeongjin AhnVP & Director · b. 1970
  • Mr. Suwoong KimHead of Business Division & MD · b. 1972

Financials

Income Statement

Currency: KRW2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue34.12B43.17B48.50B55.10B59.69B64.98B
Growth (%)-+26.51%+12.34%+13.62%+8.32%+8.87%
Gross Profit34.12B43.17B48.50B55.10B59.69B64.98B
Gross Margin100.00%100.00%100.00%100.00%100.00%100.00%
Operating Expense34.15B37.36B43.86B48.80B56.29B63.60B
Operating Income-28.58M5.81B4.64B6.30B3.40B1.38B
Operating Margin-0.08%13.47%9.56%11.44%5.70%2.13%
EBITDA--5.21B7.33B5.15B2.36B
EBITDA Margin--10.75%13.30%8.62%3.64%
Net Income-19.29M-3.30B3.93B5.56B3.84B2.59B
Net Income Margin-0.06%-7.65%8.10%10.09%6.43%3.98%
Interest Expense17.07M511.01M381.08M393.73M275.35M218.21M
Interest Expense % of Total Revenue0.05%1.18%0.79%0.71%0.46%0.34%

Balance Sheet

Currency: KRW2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets14.78B71.27B70.51B77.85B85.60B84.69B
Total Liabilities1.85B40.79B34.45B35.35B38.70B36.81B
Total Equity12.93B30.48B36.06B42.23B46.91B49.42B
Cash59.13M19.45B6.51B7.26B12.12B8.85B
Total Debt1.83B-----
Net Debt1.77B-910.93M---

Cash Flow

Currency: KRW2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-48.86M2.25B2.52B3.51B2.84B-3.07B
Investing Cash Flow-25.20B13.49B-10.14B-1.80B1.68B-
Financing Cash Flow25.35B-918.89M-5.32B-958.87M231.42M-
Capital Expenditure544.51M1.25B871.95M218.94M809.02M295.50M
Free Cash Flow-28.50M968.17M1.26B3.29B2.03B-3.36B
Dividends Paid-----567.25M
FCF to OCF58.33%43.04%50.13%93.77%71.51%109.63%
Dividend Paid to FCF------16.87%

Earnings

Report DateSep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------------------------
EPS Actual-11.781.53-3.47-0.68-0.22-313.86106.9931.96132.4793.7582.2684.86100.66240.9414.31111.89175.4339.03-13.14137.9382.2619.91-28.1871.15
Surprise------------------------
Timing------------------------

Key Statistics & Ratios

Market Cap26.21B
Enterprise Value27.16B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.41
Price / Book0.54
Revenue (TTM)63.55B
Gross Profit (TTM)63.55B
EBITDA716.38M
Profit Margin2.62%
Operating Margin0.99%
Return on Equity-2.23%
Return on Assets-0.33%
Shares Outstanding11.49M
Shares Float10.04M
Beta0.04
Dividend Yield2.19%
Dividend Rate50.00
Payout Ratio34.45%

Dividends

20251×
50.00Dec 29, 2025
20241×
50.00Dec 27, 2024

Stock Splits

  • Jun 30, 20261:5